FDA Works to Ensure Smooth Regulatory Transition of Insulin and Other Biological Products

February 20, 2020 FDA

Today, the U.S. Food and Drug Administration took additional steps to ensure a smooth regulatory transition aimed at increasing patient access to insulin products, as well as certain other biological products set to transition regulatory pathways in March

Previous Article
FDA Takes Action with Indian Government to Protect Consumers From Illicit Medical Products
FDA Takes Action with Indian Government to Protect Consumers From Illicit Medical Products

The FDA announced that in partnership with the Government of India, approximately 500 shipments of illicit ...

Next Article
FDA Announces Collaborative Review of Scientific Evidence to Support Associations Between Genetic Information and Specific Medications
FDA Announces Collaborative Review of Scientific Evidence to Support Associations Between Genetic Information and Specific Medications

FDA is providing its view of the state of the current science in pharmacogenetics. FDA’s new web-based reso...